Chromosome 16q24 deletion and decreased E-cadherin expression: possible association with metastatic potential in prostate cancer

Prostate. 1998 Jun 15;36(1):31-8. doi: 10.1002/(sici)1097-0045(19980615)36:1<31::aid-pros5>3.0.co;2-e.

Abstract

Background: Deletion of chromosome 16q is a frequent aberration in prostatic carcinoma, indicating the existence of candidate tumor suppressor genes involved in the pathogenesis of prostate cancer.

Methods: Chromosome 16 numerical aberration and loss of 16q were studied by fluorescence in situ hybridization in 31 primary and 22 metastatic tumors from 53 patients. The results were compared with E-cadherin expression, tumor grade and stage, and DNA ploidy.

Results: Numerical chromosome 16 aberrations, 16q deletion, and loss of E-cadherin expression were found in 29%, 35%, and 29% of the primary tumors, respectively, and in 73%, 73%, and 73% of the metastases, respectively. High tumor grade and DNA aneuploidy were also found to have significant correlation with metastases.

Conclusions: Deletion of chromosome 16q24 and/or loss of the E-cadherin function appears in a high frequency in metastases of prostate cancer. The strong correlations suggest that they may be important risk factors, contributing to the metastatic potential of the tumor.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / chemistry
  • Adenocarcinoma / genetics*
  • Adenocarcinoma / pathology
  • Cadherins / analysis*
  • Chromosome Aberrations
  • Chromosome Deletion*
  • Chromosome Mapping
  • Chromosomes, Human, Pair 16*
  • Genes, Tumor Suppressor*
  • Humans
  • Immunohistochemistry
  • In Situ Hybridization, Fluorescence
  • Male
  • Neoplasm Metastasis
  • Neoplasm Staging
  • Ploidies
  • Prostatic Hyperplasia / genetics
  • Prostatic Neoplasms / chemistry
  • Prostatic Neoplasms / genetics*
  • Prostatic Neoplasms / pathology

Substances

  • Cadherins